$-0.38 EPS Expected for Verastem, Inc. (VSTM)

March 15, 2018 - By Stephen Andrade

 $ 0.38 EPS Expected for Verastem, Inc. (VSTM)
Investors sentiment increased to 1.4 in 2017 Q3. Its up 0.23, from 1.17 in 2017Q2. It increased, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported.
Rbf Capital Limited Com has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM) for 11,580 shares. Alpine Woods Cap Invsts Ltd invested in 50,040 shares or 0.01% of the stock. Dimensional Fund Ltd Partnership reported 561,969 shares. Raymond James Assocs holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 58,406 shares. Jacobs Levy Equity Mngmt Inc has 160,390 shares for 0.01% of their portfolio. Grp One Trading Lp owns 52,579 shares for 0% of their portfolio. Bridgeway Inc invested in 0.01% or 228,200 shares. Blackrock Incorporated holds 0% in Verastem, Inc. (NASDAQ:VSTM) or 967,593 shares. Howland Capital Mngmt invested 0.11% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Stifel Financial has invested 0.01% in Verastem, Inc. (NASDAQ:VSTM). Two Sigma Limited Liability Company has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM) for 13,732 shares. First Manhattan reported 600 shares. Cubist Systematic Strategies Ltd Limited Liability Company has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM). Northern Trust Corp reported 66,519 shares. 100,000 were reported by Highbridge Capital Management Ltd Liability Com.

Analysts expect Verastem, Inc. (NASDAQ:VSTM) to report $-0.38 EPS on March, 22.They anticipate $0.06 EPS change or 18.75 % from last quarter’s $-0.32 EPS. After having $-0.61 EPS previously, Verastem, Inc.’s analysts see -37.70 % EPS growth. The stock decreased 1.18% or $0.04 during the last trading session, reaching $3.34. About 146,992 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since March 15, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 11 analysts covering Verastem (NASDAQ:VSTM), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Verastem had 30 analyst reports since September 9, 2015 according to SRatingsIntel. On Wednesday, September 6 the stock rating was upgraded by Cantor Fitzgerald to “Overweight”. As per Thursday, November 30, the company rating was initiated by Roth Capital. The stock has “Buy” rating by Oppenheimer on Wednesday, July 12. The firm has “Strong Buy” rating by Raymond James given on Wednesday, September 9. The rating was maintained by Oppenheimer with “Buy” on Tuesday, August 8. The company was initiated on Thursday, March 8 by FBR Capital. The company was downgraded on Tuesday, September 29 by Raymond James. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 16. On Tuesday, September 29 the stock rating was downgraded by JMP Securities to “Mkt Perform”. The firm has “Buy” rating given on Wednesday, December 13 by H.C. Wainwright.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $168.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More important recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Businesswire.com which released: “Verastem to Present at the 30” on February 26, 2018, also Businesswire.com published article titled: “Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”, Businesswire.com published: “Verastem Reports Year-End 2017 Financial Results” on March 13, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) was released by: Businesswire.com and their article: “Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference” with publication date: March 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: